ID29856A - Penggunaan antagonis reseptor at-1 atau modulator reseptor at-2 untuk mengobati penyakit yang berkaitan dengan peningkatan reseptor-reseptor at-1 atau at-2 - Google Patents

Penggunaan antagonis reseptor at-1 atau modulator reseptor at-2 untuk mengobati penyakit yang berkaitan dengan peningkatan reseptor-reseptor at-1 atau at-2

Info

Publication number
ID29856A
ID29856A IDW00200101299Q ID20010012Q ID29856A ID 29856 A ID29856 A ID 29856A ID W00200101299 Q IDW00200101299 Q ID W00200101299Q ID 20010012 Q ID20010012 Q ID 20010012Q ID 29856 A ID29856 A ID 29856A
Authority
ID
Indonesia
Prior art keywords
receptors
modulators
treat
relating
relationship
Prior art date
Application number
IDW00200101299Q
Other languages
English (en)
Indonesian (id)
Inventor
Gillian Rosemary Bullock
Marc De Gasparo
Sabina Maria Ganter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29856(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/fr
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID29856A publication Critical patent/ID29856A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IDW00200101299Q 1998-12-23 1999-12-22 Penggunaan antagonis reseptor at-1 atau modulator reseptor at-2 untuk mengobati penyakit yang berkaitan dengan peningkatan reseptor-reseptor at-1 atau at-2 ID29856A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98811258A EP1013273A1 (fr) 1998-12-23 1998-12-23 Utilisation des antagonistes du recepteur AT-1 ou des modulateurs du recepteur AT-2 pour le traitement de maladies asocciées à une augmentation de recepteurs AT-1 ou AT-2
EP98811257 1998-12-23

Publications (1)

Publication Number Publication Date
ID29856A true ID29856A (id) 2001-10-18

Family

ID=26152118

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101299Q ID29856A (id) 1998-12-23 1999-12-22 Penggunaan antagonis reseptor at-1 atau modulator reseptor at-2 untuk mengobati penyakit yang berkaitan dengan peningkatan reseptor-reseptor at-1 atau at-2

Country Status (26)

Country Link
EP (3) EP2298298A3 (fr)
JP (2) JP2002533390A (fr)
KR (1) KR100646716B1 (fr)
CN (2) CN1304000C (fr)
AT (2) ATE354364T1 (fr)
AU (4) AU3043000A (fr)
BR (1) BR9916576A (fr)
CA (2) CA2351357A1 (fr)
CY (2) CY1106581T1 (fr)
CZ (2) CZ297795B6 (fr)
DE (1) DE69935249T2 (fr)
DK (2) DK1588706T3 (fr)
ES (2) ES2373556T3 (fr)
HK (1) HK1038888B (fr)
HU (1) HUP0104780A3 (fr)
ID (1) ID29856A (fr)
IL (5) IL143233A0 (fr)
NO (2) NO328775B1 (fr)
NZ (3) NZ587909A (fr)
PL (1) PL199100B1 (fr)
PT (2) PT1588706E (fr)
RU (3) RU2271809C2 (fr)
SI (2) SI1588706T1 (fr)
SK (1) SK9132001A3 (fr)
TR (7) TR200101784T2 (fr)
WO (1) WO2000038676A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2333757C2 (ru) * 2000-06-22 2008-09-20 Новартис Аг Фармацевтические композиции
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
WO2002083127A1 (fr) * 2001-04-09 2002-10-24 Tokai University Educational System Compositions inhibant la modification proteique
CA2449150C (fr) 2001-05-31 2011-07-12 Vicore Pharma Ab Composes tricycliques utiles comme agonistes de l'angiotensine ii
EP1444988A4 (fr) * 2001-11-13 2007-04-25 Takeda Pharmaceutical Agents anticancer
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1680095A2 (fr) * 2003-11-03 2006-07-19 Zentiva, a.s. Preparation contenant du valsartan
ES2425567T3 (es) * 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Método de tratamiento o profilaxis
EA012392B1 (ru) 2004-12-24 2009-10-30 Крка, Д.Д. Ново Место Твердая фармацевтическая композиция, содержащая валсартан
WO2006136916A2 (fr) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Particules micronisees sensiblement pures de telmisartan et compositions pharmaceutiques renfermant celles-ci
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2139473A1 (fr) * 2007-03-29 2010-01-06 Alembic Limited Formulations de comprimés de valsartan
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
JP2011500577A (ja) 2007-10-09 2011-01-06 ノバルティス アーゲー バルサルタンの医薬製剤
JP5653218B2 (ja) * 2007-11-06 2015-01-14 ノバルティス アーゲー アンジオテンシン受容体アンタゴニスト／ブロッカーおよび中性エンドペプチダーゼ（ｎｅｐ）阻害剤の超構造に基づく二作用性医薬組成物
WO2009092052A2 (fr) * 2008-01-18 2009-07-23 Massachusetts Eye And Ear Infirmary Procédés et compositions pour traiter des polypes
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
EP2405899A2 (fr) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Préparations de valsartan
EP2536396B1 (fr) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
EP2455388A1 (fr) 2010-11-23 2012-05-23 LanthioPep B.V. Nouveaux agonistes du récepteur 2 (AT2) de type angiotensine et leurs utilisations
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098576A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique de valsartan à libération immédiate
WO2013098578A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
CN114514032A (zh) 2019-08-02 2022-05-17 兰提欧派普有限公司 用于治疗癌症的血管紧张素2型(at2)受体激动剂
EP4295839A1 (fr) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combinaison de valsartan et d'indapamide
WO2024026528A1 (fr) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Régime posologique pour le traitement de la bpco

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (fr) 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
ES2060737T3 (es) * 1988-02-25 1994-12-01 Yamanouchi Europ Bv Procedimiento de preparacion de un granulado farmaceutico.
SG52330A1 (en) 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
CA2093125C (fr) * 1990-10-02 2003-12-16 Warner-Lambert Company Antagonistes de l'angiotensine ii
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
NZ251741A (en) 1992-04-13 1997-06-24 Zeneca Ltd Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity
US5610153A (en) 1992-12-11 1997-03-11 Ciba-Geigy Corporation Benzazepinone derivatives
HUT71557A (en) 1992-12-11 1995-12-28 Ciba Geigy Ag Substituted benzazepinones, process for producing them and pharmaceutical compositions containing them
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995024901A1 (fr) 1994-03-17 1995-09-21 Ciba-Geigy Ag Traitement de la nephropathie diabetique a l'aide de valsartan
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
CA2232663C (fr) 1995-10-06 2008-04-08 Novartis Ag Antagonistes du recepteur d'at1 destines a prevenir et traiter l'insuffisance renale postischemique et a proteger des reins ischemies
AU2316997A (en) 1996-02-27 1997-09-16 David H Thompson Liposomal delivery system
JP4369994B2 (ja) * 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト アポトーシスの刺激のためのａｔ▲下１▼レセプターアンタゴニスト
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
ID27664A (id) * 1998-07-10 2001-04-19 Novartis Ag Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsium
NZ513039A (en) 1999-01-26 2003-11-28 Novartis Ag Use of angiotensin II receptor antagonists for treating acute myocardial infarction
RU2333757C2 (ru) * 2000-06-22 2008-09-20 Новартис Аг Фармацевтические композиции
WO2005039637A2 (fr) 2003-10-17 2005-05-06 Novartis Ag Combinaisons
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
HK1038888B (zh) 2007-09-21
NO20013143L (no) 2001-08-16
ATE524176T1 (de) 2011-09-15
CA2351357A1 (fr) 2000-07-06
EP2298298A2 (fr) 2011-03-23
IL179016A0 (en) 2007-03-08
NZ587909A (en) 2012-05-25
CZ20012306A3 (cs) 2001-12-12
EP1588706B1 (fr) 2011-09-14
IL143233A (en) 2007-07-24
SI1588706T1 (sl) 2012-01-31
NZ511938A (en) 2004-02-27
ES2281978T3 (es) 2007-10-01
SK9132001A3 (en) 2002-01-07
NO20100041L (no) 2001-08-16
DE69935249T2 (de) 2007-10-31
CY1106581T1 (el) 2012-01-25
JP2010090169A (ja) 2010-04-22
EP2298298A3 (fr) 2011-05-11
HK1038888A1 (en) 2002-04-04
IL143233A0 (en) 2002-04-21
TR200101784T2 (tr) 2001-10-22
DK1140071T3 (da) 2007-06-04
AU3043000A (en) 2000-07-31
AU2009220022B2 (en) 2011-11-03
KR20010089681A (ko) 2001-10-08
HUP0104780A2 (hu) 2002-04-29
ATE354364T1 (de) 2007-03-15
EP1140071B1 (fr) 2007-02-21
NO328775B1 (no) 2010-05-10
CA2622805A1 (fr) 2000-07-06
JP2002533390A (ja) 2002-10-08
CZ293257B6 (cs) 2004-03-17
TR200805740T1 (tr) 2010-06-21
TR200805741T2 (tr) 2008-10-21
RU2271809C2 (ru) 2006-03-20
RU2005124363A (ru) 2007-02-10
EP1588706A2 (fr) 2005-10-26
IL179015A0 (en) 2007-03-08
CN1304000C (zh) 2007-03-14
KR100646716B1 (ko) 2006-11-17
AU2003266433A1 (en) 2004-01-08
CA2622805C (fr) 2011-05-10
PT1140071E (pt) 2007-05-31
IL179017A0 (en) 2007-03-08
CY1112395T1 (el) 2015-12-09
AU2009220022A1 (en) 2009-10-15
TR200805275T2 (tr) 2008-09-22
NZ553010A (en) 2008-09-26
CN1331590A (zh) 2002-01-16
TR200200764T2 (tr) 2002-07-22
PL349424A1 (en) 2002-07-29
RU2008143545A (ru) 2010-05-10
PL199100B1 (pl) 2008-08-29
SI1140071T1 (sl) 2007-08-31
JP5254258B2 (ja) 2013-08-07
NO20013143D0 (no) 2001-06-22
TR200605471T2 (tr) 2006-11-21
DK1588706T3 (da) 2012-01-16
DE69935249D1 (de) 2007-04-05
AU2003266433B2 (en) 2006-08-10
CN1636561A (zh) 2005-07-13
PT1588706E (pt) 2011-12-21
BR9916576A (pt) 2001-10-02
TR200605472T1 (tr) 2007-02-21
EP1140071A1 (fr) 2001-10-10
ES2373556T3 (es) 2012-02-06
HUP0104780A3 (en) 2002-11-28
AU2006203077B2 (en) 2009-10-08
AU2006203077A1 (en) 2006-08-10
CZ297795B6 (cs) 2007-03-28
RU2361575C2 (ru) 2009-07-20
EP1588706A3 (fr) 2005-12-07
WO2000038676A1 (fr) 2000-07-06

Similar Documents

Publication Publication Date Title
ID29856A (id) Penggunaan antagonis reseptor at-1 atau modulator reseptor at-2 untuk mengobati penyakit yang berkaitan dengan peningkatan reseptor-reseptor at-1 atau at-2
IL146871A0 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
MXPA03007513A (es) Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
IT1276167B1 (it) Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni
ID29818A (id) Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial
HU9202990D0 (en) A new application of quisqualate receptor antagonists
ATE234098T1 (de) 4-aminopyrrole (3,2-d) pyrimidinen als antagonisten des neuropeptide y receptors
WO2002007726A8 (fr) Traitement de troubles moteurs